Monn, James A.

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine

Schizophrenia research and treatmentNeuroscience and Neuropharmacology Research

Cited by 1,040

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery

Neuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

Cited by 607

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits

Witkin, J. M., Monn, J. A., Schoepp, D. D., Li, X., Overshiner, C., Mitchell, S. N., Carter, G., Johnson, B., Rasmussen, K., & Rorick-Kehn, L. M. (2016) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 105

LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats

Helton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., & Kallman, M. J. (1997) · Neuropharmacology

Smoking Behavior and CessationNeuroscience and Neuropharmacology Research

Cited by 103

Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic–pituitary–adrenal axis and noradrenergic function

Coplan, J. D., Mathew, S. J., Smith, E. L. P., Trost, R. C., Scharf, B. A., Martinez, J., Gorman, J. M., Monn, J. A., Schoepp, D. D., & Rosenblum, L. A. (2001) · CNS Spectrums

Stress Responses and CortisolNeuroscience and Neuropharmacology Research

Cited by 18